Evidence map›Paper›PMID 42540038›Full record

ArticleSkin health and disease2026

Spironolactone for the treatment of acne vulgaris affecting female patients aged ≤ 18 years: results from a UK and Irish Survey of healthcare professionals.

Zahra Moledina, Lisa O'Higgins, Myranda Attard, Julia Fordham, Grishma Ramesh, Fiona Sexton, Lydia Tutt, Alison Layton, Miriam Santer, Jane Ravenscroft and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zahra MoledinaDepartment of Dermatology, King's College Hospital NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0003-3178-6299
Lisa O'HigginsDepartment of Dermatology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
Myranda AttardDepartment of Dermatology, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, UK.
Julia FordhamDepartment of Dermatology, Torbay and South Devon NHS Foundation Trust, Torbay Hospital, Torquay, UK.
Grishma RameshDepartment of Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Fiona SextonDepartment of Dermatology St James's Hospital, Trinity College Dublin, Dublin, Ireland.ORCID https://orcid.org/0009-0000-3404-8289
Lydia TuttCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
Alison LaytonHull York Medical School, Department of Dermatology, University of York, York, UK.
Miriam SanterPrimary Care Research Centre, University of Southampton, Southampton, UK.
Jane RavenscroftPaediatric Dermatology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK.ORCID https://orcid.org/0000-0002-1609-7084
Susannah GeorgeDepartment of Dermatology, Brighton and Sussex University Hospitals NHS Foundation Trust, Worthing, UK.
Esther Burden-TehDepartment of Dermatology, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0002-0033-2836

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A survey of UK and Irish healthcare professionals was distributed via the UK Dermatology Clinical Trials Network, British Society for Paediatric and Adolescent Dermatologists, Irish Association of Dermatologists and other regional groups. The aim was to understand how healthcare professionals prescribe spironolactone for female patients, with a particular focus on those aged ≤ 18 years, as well as concerns regarding side effects and thoughts about a future clinical trial. A total of 116 responses were received from healthcare professionals, including dermatologists, dermatology nurses, paediatricians, general practitioners and pharmacists. The results showed that there is varied clinical practice and confidence among healthcare professionals treating this population with spironolactone, with the main safety concerns being around hormonal implications, future pregnancies and lack of long-term data.

Identifiers

PMID42540038
PMCPMC13424999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.